Stroke, Vol 24, 994-999, Copyright © 1993 by American Heart Association
DC Hess, JC Sheppard and RJ Adams
BACKGROUND AND PURPOSE: There is a strong link between antiphospholipid
antibodies and stroke. The mechanism of action of antiphospholipid
antibodies is unknown. Most theories of pathogenesis center around platelet
or endothelial cell dysfunction. Our aim was to determine if there were
immunoglobulins in the sera of patients with antiphospholipid antibodies
that bind human brain microvascular endothelial cells. METHODS: We studied
sera from three groups of subjects: patients with antiphospholipid
antibodies and stroke (group 1), healthy control subjects (group 2), and
patients with stroke but without antiphospholipid antibodies (group 3). We
isolated human brain microvascular endothelial cells from temporal
lobectomy specimens and used a cellular enzyme-linked immunosorbent assay
(ELISA) to measure immunoglobulin binding to endothelial cells derived from
human brain and from human umbilical vein. We used a chromium release assay
to measure cytotoxicity. RESULTS: Patients with antiphospholipid antibodies
and stroke had significantly higher immunoglobulin binding to human brain
microvascular endothelial cells than subjects in the other groups ([ELISA
index+standard deviation], 63 +/- 37 [group 1] versus 7 +/- 7 [group 2]
versus 7 +/- 7 [group 3], P < .001). There was, however, poor
correlation between binding to brain endothelial cells and binding to
cardiolipin. The binding to brain microvascular cells was not specific to
brain endothelium, as similar results were found in an ELISA using human
umbilical vein cells. There was no evidence of complement-mediated brain
endothelial cell cytotoxicity. CONCLUSIONS: Patients with stroke and
antiphospholipid antibodies frequently have human brain microvascular
endothelial-reactive antibodies in their serum. These antibodies are
distinct from those to cardiolipin. We found no evidence that these
antibodies are cytotoxic.
ARTICLES
Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies
Department of Neurology, Medical College of Georgia, Augusta.
This article has been cited by other articles:
![]() |
R Cimaz, P L Meroni, and Y Shoenfeld Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome) Lupus, April 1, 2006; 15(4): 191 - 197. [Abstract] [PDF] |
||||
![]() |
A Katzav, J Chapman, and Y Shoenfeld CNS dysfunction in the antiphospholipid syndrome Lupus, December 1, 2003; 12(12): 903 - 907. [Abstract] [PDF] |
||||
![]() |
P L Meroni, A Tincani, N Sepp, E Raschi, C Testoni, E Corsini, I Cavazzana, S Pellegrini, and A Salmaggi Endothelium and the brain in CNS lupus Lupus, December 1, 2003; 12(12): 919 - 928. [Abstract] [PDF] |
||||
![]() |
R L Brey, J Chapman, S R Levine, G Ruiz-Irastorza, R H. Derksen, M Khamashta, and Y Shoenfeld Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 Lupus, July 1, 2003; 12(7): 508 - 513. [Abstract] [PDF] |
||||
![]() |
Y Shoenfeld, A Nahum, A D Korczyn, M Dano, R Rabinowitz, O Beilin, C G Pick, L Leider-Trejo, L Kalashnikova, M Blank, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer Lupus, June 1, 2003; 12(6): 436 - 442. [Abstract] [PDF] |
||||
![]() |
E. Ahmed, B. Stegmayr, J. Trifunovic, L. Weinehall, G. Hallmans, and A. K. Lefvert Anticardiolipin Antibodies Are Not an Independent Risk Factor for Stroke : An Incident Case-Referent Study Nested Within the MONICA and Vasterbotten Cohort Project Stroke, June 1, 2000; 31(6): 1289 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Hess Models for Central Nervous System Complications of Antiphospholipid Syndrome Lupus, August 1, 1994; 3(4): 253 - 257. [Abstract] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1993 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |